Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1984 1
1985 1
1988 2
1989 1
1990 2
1997 1
2015 3
2016 3
2017 2
2018 1
2019 2
2020 7
2021 9
2022 9
2023 12
2024 25
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Short NJ, et al. Among authors: nasr lf. J Clin Oncol. 2024 May 1;42(13):1499-1508. doi: 10.1200/JCO.23.01911. Epub 2024 Jan 26. J Clin Oncol. 2024. PMID: 38277619 Clinical Trial.
Central Nervous System Prophylaxis and Treatment in Acute Leukemias.
Wu SY, Short NJ, Nasr L, Dabaja BS, Fang PQ. Wu SY, et al. Among authors: nasr l. Curr Treat Options Oncol. 2022 Dec;23(12):1829-1844. doi: 10.1007/s11864-022-01032-5. Epub 2022 Dec 13. Curr Treat Options Oncol. 2022. PMID: 36510037 Free PMC article. Review.
Systemic AL amyloidosis: current approach and future direction.
Bou Zerdan M, Nasr L, Khalid F, Allam S, Bouferraa Y, Batool S, Tayyeb M, Adroja S, Mammadii M, Anwer F, Raza S, Chaulagain CP. Bou Zerdan M, et al. Among authors: nasr l. Oncotarget. 2023 Apr 26;14:384-394. doi: 10.18632/oncotarget.28415. Oncotarget. 2023. PMID: 37185672 Free PMC article. Review.
Kienbock Disease.
Nasr LA, Koay J. Nasr LA, et al. 2023 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 30725676 Free Books & Documents.
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. Short NJ, et al. Among authors: nasr l. Blood Adv. 2024 Feb 27;8(4):909-915. doi: 10.1182/bloodadvances.2023012231. Blood Adv. 2024. PMID: 38207208 Free PMC article. Clinical Trial.
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia.
Short NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, Gibson A, Jain N, Haddad FG, Nasr LF, Marx KR, Rausch C, Savoy JM, Garris R, Ravandi F, Kantarjian H. Short NJ, et al. Among authors: nasr lf. Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):e168-e173. doi: 10.1016/j.clml.2023.12.016. Epub 2023 Dec 30. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38212207
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL.
Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, Kanagal-Shamanna R, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Garris R, Nasnas C, Nasr L, Ravandi F, Jabbour E. Kantarjian H, et al. Among authors: nasr l. J Clin Oncol. 2024 Dec 20;42(36):4246-4251. doi: 10.1200/JCO.24.00272. Epub 2024 Jul 19. J Clin Oncol. 2024. PMID: 39028925
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips AH, Khoury J, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris RS, Nasr LF, Kriwacki RW, Roberts KG, Konopleva M, Jabbour EJ, Mullighan CG. Zhao Y, et al. Among authors: nasr lf. Blood. 2024 Jul 4;144(1):61-73. doi: 10.1182/blood.2024023930. Blood. 2024. PMID: 38551807
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. Short NJ, et al. Among authors: nasr l. J Hematol Oncol. 2023 Jul 8;16(1):73. doi: 10.1186/s13045-023-01476-8. J Hematol Oncol. 2023. PMID: 37422688 Free PMC article. Clinical Trial.
Mechano-dependent sorbitol accumulation supports biomolecular condensate.
Torrino S, Oldham WM, Tejedor AR, Burgos IS, Nasr L, Rachedi N, Fraissard K, Chauvet C, Sbai C, O'Hara BP, Abélanet S, Brau F, Favard C, Clavel S, Collepardo-Guevara R, Espinosa JR, Ben-Sahra I, Bertero T. Torrino S, et al. Among authors: nasr l. Cell. 2024 Nov 16:S0092-8674(24)01271-6. doi: 10.1016/j.cell.2024.10.048. Online ahead of print. Cell. 2024. PMID: 39591966
74 results